title: Surveying the landscape of MDS/MPN research: overlap among the overlap syndromes?
abstract: The myelodysplastic/myeloproliferative neoplasms (MDS/MPNs) lie at the interphase of phenotypically opposing bone marrow malignancies. They are characterized by concomitant features of bone marrow failure and myeloproliferation and are generally associated with a poor prognosis. Although much is unknown with respect to the clinical course and molecular biology of MDS/MPNs, emerging research is beginning to uncover the key defining characteristics of this designation. In this review, we will discuss the features of MDS/MPN diseases that unify there clinical and molecular course and those that define distinct disease entities. We will discuss advances in genetics and MDS/MPN modeling, as well as translational discoveries that are anticipated to inform the diagnosis, prognostication, and treatment of MDS/MPNs in the near future.
authors.affiliation: Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.
authors.forename: Eric
authors.initials: E
authors.lastname: Padron
mesh_terms: D000818:Animals; D019046:Bone Marrow Neoplasms / Q000175:diagnosis / Q000235:genetics; D002986:Clinical Trials as Topic; D015894:Genome, Human; D023281:Genomics; D006405:Hematology / Q000379:methods; D006801:Humans; D008495:Medical Oncology / Q000379:methods; D008745:Methylation; D051379:Mice; D009154:Mutation; D009190:Myelodysplastic Syndromes / Q000175:diagnosis* / Q000235:genetics / Q000628:therapy; D054437:Myelodysplastic-Myeloproliferative Diseases / Q000175:diagnosis* / Q000235:genetics / Q000628:therapy; D010641:Phenotype; D011379:Prognosis; D057170:Translational Research, Biomedical; D014944:World Health Organization